Trial Profile
An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 as 2 Line Therapy for Patients With Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 17 Mar 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 17 Mar 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 06 Nov 2005 New trial record.